Ed joined Rheos as Chief Technology Officer and has over 15 years of scientific and technology experience in emerging biotechnology companies. Prior to joining Rheos, Ed created and led the Cell Metabolism Department at Agios Pharmaceuticals where he built an industry-leading platform for metabolism discovery and was a co-author of publications in Immunity, Nature, and Science which documented the discovery of 2HG production by IDH-mutant tumors that has led to the development of Idhifa and other treatments for acute myelogenous leukemia. Prior to Agios, he held R&D roles at Ensemble Discovery and Microbia, Inc. and is a Founder and Managing Partner of General Metabolics, LLC, a boutique contract research group supporting academic and industrial researchers in metabolomics. Ed completed a NSF-Sloan Post-Doctoral Fellow at Stanford University, studying molecular evolution.
Ed earned his Ph.D. in Bio-organic Chemistry at the University of California, Berkeley and an S.B. in Biological Chemistry at the University of Chicago.